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Abstract 
Accessory male breast cancer (BC) is a rare entity and is associated with poor outcome. We 
report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary 
lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation. He received concurrent 
radiation and platinum-based chemotherapy for lung cancer with good response, but breast 
cancer progressed in about 8 months, and further progressed after single agent anastrozole 
in 10 months. Next Generation Sequencing (NGS) of breast cancer was also positive for CCND1 
(Cyclin D1) and FGFR1 amplifications. Despite a poor molecular profile of breast cancer, and 
progression following platinum-based chemotherapy and anastrozole, he was successfully 
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treated with the Cyclin-dependent kinase (CKD) 4/6 inhibitor palbociclib, estrogen-receptor 
down-regulator fulvestrant and luteinizing hormone-releasing hormone (LHRH) agonist 
leuprolide with the duration of response of 21 months which has exceeded duration of re-
sponse to prior treatments. This case is of interest given FDA expanded the approval of palbo-
ciclib in combination with AI or fulvestrant for male patients with HR–positive, HER2-negative 
metastatic breast cancer in Apr. 2019 based on real-world data from electronic health records. 
 © 2019 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Accessory breast cancer is very rare, accounting for 0.3–0.6% of all breast cancers, it 
mostly presents as an axillary mass and can also grow in any part of the breast line (the line 
from axilla to groin) [1]. Males BC is almost exclusively hormone receptor positive, including 
the androgen receptor (AR), and is associated with a higher prevalence of BRCA 2 germline 
mutations. The mainstay of systemic therapy for hormone receptor (HR)-positive male breast 
cancer is hormonal therapy. Tamoxifen is the most extensively studied. Other hormonal ther-
apies include LHRH agonists, aromatase inhibitors (AIs), and fulvestrant have also been used 
in adjuvant and or metastatic settings. CDK inhibitors or mammalian target of rapamycin 
(mTOR) inhibitors used in combination therapy, as compared with endocrine therapy alone, 
have been reported to result in significantly improved outcomes in women with breast cancer 
[2–4]. Unfortunately, data on such treatment in male BC is lacking.  
Case Report 
We present the case of 76-year-old male with metastatic accessory breast cancer, who 
was successfully treated with combination of CKD4/6 inhibitor palbociclib, estrogen-receptor 
down-regulator fulvestrant and LHRH agonist leuprolide.  
In January 2016, patient presented to the outside of hospital with a slowly growing right 
axillary mass over 3 years course. An excisional biopsy of the axillary mass was performed 
and invasive ductal carcinoma (IDC) of breast [estrogen receptor (ER)+, progesterone recep-
tor (PR)+ and human epidermal growth factor receptor-2 (HER2)–] was diagnosed. A positron 
emission tomography/computed tomography (PET/CT) suggested uptake in right axillary 
and subcarinal lymph nodes, right parotid lesion, prostate, and two lung nodules in the right 
lower lobe measured 1 cm with SUV of 1.4 and 1.6. Subsequently the patient underwent right 
axillary tumor bed resection and sentinel lymph node (SLN) dissection. Final biopsy results of 
the mass showed IDC, grade 3, stage II pT2N0M0, ER+/PR+/HER–. Oncotype DX score was 27. 
And Foundation One NGS was positive for BRCA2 (E1593D) mutation as well as CCND1 (Cyclin 
D1) and FGFR1 amplifications. Genetic test was negative for genetic mutation. 
An endobronchial ultrasound (EBUS) and fine needle aspiration (FNA) of subcarinal 
lymph node were performed and showed poorly differentiated carcinoma. Immunohisto-
chemistry (ICH) studies were consistent with primary lung adenocarcinoma with positive for 
TTF-1, NapsinA, and Keratin and negative for mammoglobin, ER, PR, and HER2. A core biopsy 
result of the right lung was suggestive of invasive adenocarcinoma. The patient was therefore 
diagnosed with stage IIIA NSCLC. Subsequently from Mar. to Apr. 2016, he underwent concur-
rent chemoradiation with three cycles of paclitaxel and carboplatin as well as a total 4,500 cGy 
radiation therapy in 25 fractions to the right lower lobe and subcarinal lymph node. In May 
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2016, PET/CT revealed a decrease in size of the hypermetabolic subcarinal lymph node. In 
June 2016, the patient underwent right lower lobe superior subsegmentectomy along with 
hilar and mediastinal lymph node dissection. Pathologic results suggested well differentiated 
to moderate differentiated adenocarcinoma, 1.6 cm with clean margins, no lymphovascular 
involvement, 0/7 lymph nodes involvement (ypT1aN0M0). IHC results consisted of negative 
EGFR, ALK, ROS1, and PDL1 22C3 INC 0%. Foundation One NGS was positive for BRCA2 
(E1593D) mutation.  
A complicated chylothorax, respiratory failure, and prolonged rehabilitation delayed 
starting anastrozole for breast cancer till Oct 2016, when a baseline PET/CT showed metasta-
sis in right proximal femur. Patient subsequently transferred care to our institution, and 
PET/CT in August 2017 showed tumor progression. PET avid areas included right axillary 
lymph node, right proximal femur and right lower lobe pleural nodule (Fig. 1a). Subsequently 
an ultrasound-guided right axillary lymph node core biopsy and an FNA of right femur bone 
were performed. IHC results confirmed metastatic breast carcinoma with ER 100%, PR 95%, 
HER2 IHC/FISH negative and Ki 67 30–40%. Anastrozole was discontinued and patient was 
started on palbociclib, fulvestrant and leuprolide while continuing zometa. Patient has been 
tolerating the three-drug combination therapy relatively well except mild neutropenia, for 
which palbociclib had been decreased to 100 mg dosing. A series of CTs have showed very 
good response with the most recent PET/CT in February 2019 demonstrating complete reso-
lution of right axillary lymph node, resolution of pleural nodules and minimally sclerotic le-
sion in the right femur (Fig. 1b). 
Discussion and Review of Literature 
To our knowledge, this is the first case report showing a clinically meaningful response 
to a combination of CKD 4/6 inhibitor, fulvestrant and LHRH agonist in metastatic male breast 
cancer.  
Most data regarding treatment of male breast cancer is retrospective and comes from 
small single-institution series, thus the choice of treatment modalities is generally guided by 
extrapolation of data from female breast cancer. Since male BC is almost always ER+, the pre-
ferred treatment option for 1st line therapy of metastatic disease is endocrine therapy. Ta-
moxifen is the treatment of choice, and upon relapse, other therapeutic options should be con-
sidered like aromatase inhibitors preferably used with LHRH agonist or fulvestrant [5]. The 
combinations of endocrine and molecular agents like CDK4/6 inhibitors have been approved 
in metastatic BC, but data specific to male breast cancer is lacking. BRCA2 mutation associated 
cancers display DNA-repair deficiency and are particularly susceptible to DNA-repair inhibi-
tion and DNA-damage with PARP inhibitors and platinum, respectively. 
Our patient had a near complete response to concurrent platinum-based chemoradiation 
therapy in the setting of BRCA2-mutation-positive lung cancer after resection, but demon-
strated eventual disease progression of BRCA 2-mutation-positive breast cancer. He had sta-
ble disease on anastrozole for about 10 months, similar to a case series of men treated with 
aromatase inhibitor with or without LHRH agonists [6]. The eventual resistance was likely 
driven by activation of feedback loop of higher FSH and LH and testicular steroidogenesis in-
duced by lower estrogen caused by anastrozole as well as due to escape signaling, likely driven 
by Cyclin D1 and FGFR1 in this patient.  
Fulvestrant, a selective estrogen-receptor down-regulator, binds competitively to ERs in 
breast cancer cells, leading to ER deformation and decreased binding of estrogen [7]. In 
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metastatic breast cancer, fulvestrant in combination with palbociclib, a CDK4/6 inhibitor was 
associated with significant PFS benefit and a trend toward overall survival compared to ful-
vestrant alone in patients whose disease had progressed after cytotoxic chemotherapy and or 
aromatase inhibitor [8]. Furthermore, LHRH agonists are known to desensitize the pituitary 
hormone (LH) and follicle-stimulating hormone (FSH) with resultant fall in ovarian estrogens. 
Indeed, in premenopausal women in PALOMA-3, LHRH agonist was added to block ovarian 
steroidogenesis. However, this study did not include male breast cancer patients. Given the 
feasibility and efficacy of adding LHRH agonist in premenopausal women in PALOMA-3, we 
used the LHRH agonist in our male patient to block testicular steroidogenesis. 
Interestingly, our patient had somatic BRCA2 E1593D mutation both in lung and breast 
cancer. The durable response of poorly differentiated lung cancer to carboplatin and paclitaxel 
and radiation was likely due to additive/synergistic effect of DNA damage inducing effect of 
concurrent platinum and radiation-based therapy. Moreover, use of both platinum-based 
therapy and PARP inhibitors has been associated with PFS benefit in metastatic BC with 
germline BRCA mutation [9–11]. We show that in a patient who had received prior platinum, 
the combination of fulvestrant and palbociclib remains efficacious even in the setting of so-
matic BRCA2 mutation. This may have further relevance in treatment of somatic and germ-
line BRCA-mutation positive patients, given efficacy of PARP inhibitors in BRCA-germ-line 
mutation positive breast cancer and for germ-line and somatic mutation ovarian cancer. 
Moreover, our patient had both Cyclin D1 (CCND1) and FGFR1 amplifications in breast cancer. 
Both Cyclin D1 and FGFR1 amplifications have been shown to predict poor clinical outcome 
in ER-positive breast cancers and are associated with the emergence of endocrine resistance. 
The combination of CKD4/6 inhibitor with AI or fulvestrant has shown consistent benefit in 
setting of Cyclin D1 amplification while FGFR1 amplification has been reported to induce re-
sistance to CDK4/6 inhibitor combination therapies both in cell lines [12] and clinical study 
[13]. Interestingly, our patient achieved a durable remission despite presence of FGFR muta-
tion, suggesting that the combination of fulvestrant, palbociclib and leuprolide may delay 
emergence of resistance. In future, upon progression, FGFR inhibitors may offer precision 
guided treatment option [14].  
Conclusion 
In this paper, we have described a very rare case of a male metastatic breast carcinoma 
arising in an accessary mammary gland. Our case shows the combination of CKD 4/6 inhibitor, 
fulvestrant and LHRH agonist has a clinically meaningful benefit in the setting of acquired en-
docrine-refractory and platinum-pretreated metastatic male breast cancer with somatic 
BRCA2 mutation, FGFR1 and Cyclin D1 amplification. Our patient was treated before the re-
cent FDA expanded approval of palbociclib in combination with AI or fulvestrant for male pa-
tients with HR–positive, HER2-negative metastatic breast cancer based on real-world data 
from electronic health records. Judicious use of medications in men based on their approval 
in female breast cancer is warranted given the rarity of male breast cancer. Our patient also 
had a good response to platinum-based chemotherapy and concomitant radiation in somatic 
BRCA2-positive lung cancer. And due to the rarity of male breast cancer, studies of breast can-
cer treatment should enroll both females and males to build an evidence base that supports 
future treatment recommendations.  
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Fig. 1. Target lesions on PET/CT before therapy (a) and after 18 months therapy (b). a., right axillary lymph 
node; b., right lower lobe pleural nodule; c., right proximal femur lesion. 
 
